Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 18/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785980 | 0.89 | CRHR1 (0.51) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL784580 | 0.89 | CRHR1 (0.51) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL803564 | 0.87 | PDE10A (0.49) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL2819704 | 0.87 | PDE10A (0.49) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL2817877 | 0.87 | TAS1R3 (0.50) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL2817878 | 0.87 | TAS1R3 (0.50) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL484334 | 0.83 | ALDH1A1 (0.58) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL784965 | 0.83 | ALDH1A1 (0.58) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL803549 | 0.83 | ALDH1A1 (0.58) | PDE4APDE4BPDE4CPDE4DTAS1R3 | |
| SCHEMBL803173 | 0.82 | TAS1R3 (0.46) | PDE4APDE4BPDE4CPDE4DTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | PDE4A 944/4885PDE4B 939/4885PDE4C 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.